Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Martha Shumway, Anne F. Luetkemeyer, Marion G. Peters, Mallory O. Johnson, Tessa M. Napoles & Elise D. Riley. (2019) Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 31:11, pages 1340-1347.
Read now
Read now
Midori Kjellin, Hege Kileng, Dario Akaberi, Navaneethan Palanisamy, Ann-Sofi Duberg, Astrid Danielsson, Magnhild Gangsøy Kristiansen, Johan Nöjd, Soo Aleman, Tore Gutteberg, Rasmus Goll, Anders Lannergård & Johan Lennerstrand. (2019) Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scandinavian Journal of Gastroenterology 54:8, pages 1042-1050.
Read now
Read now
Vasily Isakov, Vladimir Chulanov, Dzhamal Abdurakhmanov, Eduard Burnevich, Elena Nurmukhametova, Galina Kozhevnikova, Natalya Gankina, Sergey Zhuravel, Svetlana Romanova, Robert H. Hyland, Sophia Lu, Evguenia S. Svarovskaia, John McNally, Diana M. Brainard, Vladimir Ivashkin, Vyacheslav Morozov, Igor Bakulin, Martin Lagging, Konstantin Zhdanov & Ola Weiland. (2019) Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. Infectious Diseases 51:2, pages 131-139.
Read now
Read now
Francesca Romana Ponziani, Luca Miele, Annalisa Tortora, Manuele Furnari, Giorgia Bodini, Maurizio Pompili, Antonio Gasbarrini & Edoardo Giovanni Giannini. (2018) Treatment of early stage chronic hepatitis C virus infection. Expert Review of Clinical Pharmacology 11:5, pages 519-524.
Read now
Read now
Midori Kjellin, Terése Wesslén, Erik Löfblad, Johan Lennerstrand & Anders Lannergård. (2018) The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala Journal of Medical Sciences 123:1, pages 50-56.
Read now
Read now
Martin Kåberg, Anders Hammarberg, Christer Lidman & Ola Weiland. (2017) Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. Infectious Diseases 49:10, pages 728-736.
Read now
Read now
Katharina Büsch, Jesper Waldenström, Martin Lagging, Soo Aleman, Ola Weiland, Jan Kövamees, Ann-Sofi Duberg & Jonas Söderholm. (2017) Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology 52:1, pages 61-68.
Read now
Read now
Cristina Scavone, Liberata Sportiello, Concetta Rafaniello, Annamaria Mascolo, Maurizio Sessa, Francesco Rossi & Annalisa Capuano. (2016) New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety 15:sup2, pages 85-100.
Read now
Read now
Articles from other publishers (24)
Peer Brehm Christensen, Birgit Debrabant, Susan Cowan, Kristian Debrabant, Anne Øvrehus & Ann-Sofi Duberg. (2022) Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020. Eurosurveillance 27:50.
Crossref
Crossref
Soledad Colombe, Maria Axelsson, Soo Aleman, Ann-Sofi Duberg, Josefine Lundberg Ederth & Viktor Dahl. (2022) Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018. BMC Infectious Diseases 22:1.
Crossref
Crossref
Sarah Blach, Marianne Blomé, Ann‐Sofi Duberg, Anna Jerkeman, Martin Kåberg, Per‐Erik Klasa, Martin Lagging, Devin Razavi‐Shearer, Homie Razavi & Soo Aleman. (2021) Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19. Liver International 41:9, pages 2024-2031.
Crossref
Crossref
Katharina Büsch, Fredrik Hansson, Michelle Holton, Martin Lagging, Johan Westin, Jan Kövamees, Matti Sällberg & Jonas Söderholm. (2020) Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. BMJ Open 10:9, pages e035996.
Crossref
Crossref
Soo Aleman, Jonas Söderholm, Katharina Büsch, Jan Kövamees & Ann‐Sofi Duberg. (2020) Frequent loss to follow‐up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver International 40:8, pages 1832-1840.
Crossref
Crossref
Nurgul Batyrbekova, Soo Aleman, Charlotte Lybeck, Scott Montgomery & Ann-Sofi Duberg. (2020) Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden. Cancer Epidemiology, Biomarkers & Prevention 29:1, pages 63-70.
Crossref
Crossref
Karl Björkström, Stefan Franzén, Björn Eliasson, Mervete Miftaraj, Soffia Gudbjörnsdottir, Ylva Trolle-Lagerros, Ann-Marie Svensson & Hannes Hagström. (2019) Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology 17:13, pages 2769-2775.e4.
Crossref
Crossref
Kelly Safreed-Harmon, Sarah Blach, Soo Aleman, Signe Bollerup, Graham Cooke, Olav Dalgard, John F Dillon, Gregory J Dore, Ann-Sofi Duberg, Jason Grebely, Knut Boe Kielland, Håvard Midgard, Kholoud Porter, Homie Razavi, Mark Tyndall, Nina Weis & Jeffrey V Lazarus. (2019) The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases 69:12, pages 2218-2227.
Crossref
Crossref
Beuy Joob & Viroj Wiwanitkit. (2021) Required Treatment Expenditures for Hepatitis C Virus Infection and Advantage in the Reduction of Hepatocellular Carcinoma Incidence: Analysis of Possible Options in an Endemic Area. Indian Journal of Medical and Paediatric Oncology 40:04, pages 481-483.
Crossref
Crossref
Kunichika Matsumoto, Yinghui Wu, Takefumi Kitazawa, Shigeru Fujita, Kanako Seto & Tomonori Hasegawa. (2018) Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections. PLOS ONE 13:6, pages e0199188.
Crossref
Crossref
Soumana C. Nasser, Hanine Mansour, Tatiana Abi Nader & Mirna Metni. (2018) Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients. International Journal of Clinical Pharmacy 40:3, pages 693-699.
Crossref
Crossref
Hannah Fraser, Natasha K. Martin, Henrikki Brummer-Korvenkontio, Patrizia Carrieri, Olav Dalgard, John Dillon, David Goldberg, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kåberg, Amy A. Matser, Mojca Matičič, Havard Midgard, Viktor Mravcik, Anne Øvrehus, Maria Prins, Jens Reimer, Geert Robaeys, Bernd Schulte, Daniela K. van Santen, Ruth Zimmermann, Peter Vickerman & Matthew Hickman. (2018) Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology 68:3, pages 402-411.
Crossref
Crossref
Kelly Safreed-Harmon, Kristina L. Hetherington, Soo Aleman, Hannu Alho, Olav Dalgard, Tove Frisch, Magnus Gottfredsson, Nina Weis & Jeffrey V. Lazarus. (2018) Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLOS ONE 13:1, pages e0190146.
Crossref
Crossref
H. Kileng, L. Bernfort, T. Gutteberg, O.S. Moen, M.G. Kristiansen, E.J. Paulssen, L.K. Berg, J. Florholmen & R. Goll. (2017) Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infectious Diseases 17:1.
Crossref
Crossref
Nat Wright, Jens Reimer, Lorenzo Somaini, Carlos Roncero, Icro Maremmani, Nicolas Simon, Peter Krajci, Richard Littlewood, Oscar D’Agnone, Hannu Alho & Benjamin Rolland. (2017) Are we ready to treat hepatitis C virus in individuals with opioid use disorder. European Journal of Gastroenterology & Hepatology 29:11, pages 1206-1214.
Crossref
Crossref
Hayley Bennett, Jason Gordon, Beverley Jones, Thomas Ward, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner & Phil McEwan. (2016) Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. The European Journal of Health Economics 18:8, pages 1001-1011.
Crossref
Crossref
Ming-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I. Huang, Meng-Hsuan Hsieh, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai & Wan-Long Chuang. (2017) Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. Clinical Cancer Research 23:7, pages 1690-1697.
Crossref
Crossref
María Buti, Jose Luis Calleja, Javier García-Samaniego, Miguel Ángel Serra, Javier Crespo, Manuel Romero, Miguel Ángel Simón, Juan Turnes, Antonio Javier Blasco, Pablo Lázaro, Sarah Robbins & Homie Razavi. (2017) Eliminación de la hepatitis C en España: adaptación de un modelo matemático de salud pública partiendo del plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Medicina Clínica 148:6, pages 277-282.
Crossref
Crossref
María Buti, Jose Luis Calleja, Javier García-Samaniego, Miguel Ángel Serra, Javier Crespo, Manuel Romero, Miguel Ángel Simón, Juan Turnes, Antonio Javier Blasco, Pablo Lázaro, Sarah Robbins & Homie Razavi. (2017) Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. Medicina Clínica (English Edition) 148:6, pages 277-282.
Crossref
Crossref
Anna Törner, Knut Stokkeland, Åke Svensson, Paul W. Dickman, Rolf Hultcrantz, Scott Montgomery & Ann‐Sofi Duberg. (2016) The underreporting of hepatocellular carcinoma to the cancer register and a log‐linear model to estimate a more correct incidence. Hepatology 65:3, pages 885-892.
Crossref
Crossref
Ilias Gountas, Vana Sypsa, George Papatheodoridis, George Souliotis, Homie Razavi & Angelos Hatzakis. (2017) Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. Journal of Gastroenterology and Hepatology 32:2, pages 466-472.
Crossref
Crossref
Isabel Conde, Carmen Vinaixa & Marina Berenguer. (2017) Cirrosis por hepatitis C. Estado actual. Medicina Clínica 148:2, pages 78-85.
Crossref
Crossref
Isabel Conde, Carmen Vinaixa & Marina Berenguer. (2017) Hepatitis C-related cirrhosis. Current status. Medicina Clínica (English Edition) 148:2, pages 78-85.
Crossref
Crossref
John F. Dillon, Jeffrey V. Lazarus & Homie A. Razavi. (2016) Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatology, Medicine and Policy 1:1.
Crossref
Crossref